Company intelligence / Profile preview
Goldfinch Bio
Cambridge, Massachusetts, United Statesleadiq.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Goldfinch Bio showed positive preliminary data from Phase 2 trial of GFB-887 with a 32% placebo-adjusted mean reduction in urine protein creatine ratio (UPCR) in FSGS patients. In a subset identified by a novel biomarker, treatment demonstrated a 48% placebo-adjusted mean reduction in UPCR. The company was shut down in early 2023 after failing to secure additional financing.[8][2]
- Therapeutic areas
- EndocrinologyNephrology
- Modalities
- Small moleculesmonoclonal antibodies
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Request access →03
Partnerships
Beyond the preview
Go deeper on Goldfinch Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Goldfinch Bio.